Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.
BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and
BETHESDA, Md., Aug. 11, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing
©2022 Gain Therapeutics, Inc